Solid Biosciences Partners with Nanomosaic to Boost Gene Therapy Delivery
SLDB has more than doubled off its 52-week low of $3.065.
Summary
Solid Biosciences has announced a co-marketing agreement with Nanomosaic, focusing on advancing gene therapy delivery and analytics. This partnership follows a period of significant positive news for Solid Biosciences, including a $240 million private placement in March and positive interim Phase 1/2 clinical data for its SGT-003 Duchenne muscular dystrophy candidate. The agreement could enhance Solid Biosciences' technological capabilities and market position within the gene therapy sector.
At the time of this announcement, SLDB was trading at $7.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $707.9M. The 52-week trading range was $3.07 to $8.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.